The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy.
Lyudmila Bazhenova
Research Funding - NovaRX
Giuseppe Giaccone
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Erzsébet Juhász
No relevant relationships to disclose
Rodryg Ramlau
No relevant relationships to disclose
Michel M van den Heuvel
No relevant relationships to disclose
Rohit Lal
Research Funding - NovaRX
David Dunlop
No relevant relationships to disclose
Edward B. Garon
Research Funding - NovaRX
Quincy S. Chu
No relevant relationships to disclose
Minish Mahendra Jain
No relevant relationships to disclose
Ewa Carrier
No relevant relationships to disclose
Steven Moses
Employment or Leadership Position - NovaRX
Daniel Shawler
Employment or Leadership Position - NovaRX
Habib Fakhrai
Employment or Leadership Position - NovaRX
Stock Ownership - NavaRx